Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

Item
http://www.wikidata.org/entity/Q35179391
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimenFactors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South AfricaConcordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimenVirologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South AfricaWorld Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries.Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009.Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy.Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy.Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort.High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectionScience and ethics of human immunodeficiency virus/acquired immunodeficiency syndrome controversies in Africa.Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review.Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.
P2860

Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

Item
http://www.wikidata.org/entity/Q35179391
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Rapid development of antiretro ...... based therapy in South Africa.
@ast
Rapid development of antiretro ...... based therapy in South Africa.
@en
type
label
Rapid development of antiretro ...... based therapy in South Africa.
@ast
Rapid development of antiretro ...... based therapy in South Africa.
@en
prefLabel
Rapid development of antiretro ...... based therapy in South Africa.
@ast
Rapid development of antiretro ...... based therapy in South Africa.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Rapid development of antiretro ...... based therapy in South Africa.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932